Biotechnology News and Research RSS Feed - Biotechnology News and Research

Genes that influence people's health also have impact on some cognitive functions

Genes that influence people's health also have impact on some cognitive functions

Genes that influence people's health also shape how effectively they think, a study shows. Scientists found that genes associated with diseases including Alzheimer's disease, schizophrenia, and autism also have an impact on some cognitive functions. [More]
Halozyme closes $150 million royalty-backed debt transaction

Halozyme closes $150 million royalty-backed debt transaction

Halozyme Therapeutics, Inc. today announced that it has closed the previously announced $150 million royalty-backed debt transaction with investment funds managed by Pharmakon Advisors and Athyrium Capital Management. The debt is secured by future royalties of ENHANZE products, received only from Halozyme's collaborations with Roche and Baxalta. [More]
New humidity sensors could help combat proliferation of bacteria

New humidity sensors could help combat proliferation of bacteria

The Telecommunications Engineer Aitor Urrutia-Azcona has designed some humidity sensors with anti-bacterial properties that combat the proliferation of micro-organisms in environments where the humidity level is very high, such as hospitals and industrial premises for foodstuffs or pharmaceutical products. [More]
Biomedical innovation in the UK: an interview with Zahid Latif

Biomedical innovation in the UK: an interview with Zahid Latif

The biomedical research base is one of the UK's strengths; over 1500 companies in the Pharmaceuticals and biotechnology area are established in the UK employing over 70,000. [More]
Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

Amgen today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication Repatha (evolocumab) Injection, the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to be approved in Japan. [More]
Champions Oncology begins prospective correlative trial of PDX in patients with sarcoma

Champions Oncology begins prospective correlative trial of PDX in patients with sarcoma

Champions Oncology today announced that it has initiated a sponsored prospective correlative trial of patient derived xenograft modeling (PDX or Champions TumorGraft PDX models) in patients with metastatic or recurrent sarcoma. Mount Sinai Hospital in Toronto, Canada is the first clinical site to enroll patients in the newly-opened study. [More]
Oxeia accelerating development of neurometabolic treatments for concussions

Oxeia accelerating development of neurometabolic treatments for concussions

Oxeia Biopharmaceuticals, Inc., a biotechnology company, is catalyzing the development of first-in-class neurometabolic treatments for concussions and other aspects of brain injury. [More]
AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

Halozyme Therapeutics, Inc. today announced that AbbVie has dosed the first subject in a clinical trial evaluating the safety and pharmacokinetics of adalimumab with Halozyme's proprietary ENHANZE technology. [More]
Philogen launches Phase III pivotal trial in patients with Stage IIIB/C melanoma

Philogen launches Phase III pivotal trial in patients with Stage IIIB/C melanoma

Philogen S.p.A. today announced the launch of a pivotal trial in patients with Stage IIIB/C melanoma, following promising results obtained in a Phase II study with an innovative immunotherapeutic approach. [More]
CSU's BioMARC awarded DoD contract to help develop new vaccines to combat encephalitic viruses

CSU's BioMARC awarded DoD contract to help develop new vaccines to combat encephalitic viruses

Colorado State University's Biopharmaceutical Manufacturing and Academic Resource Center has been awarded a 10-month, $4.6 million contract funded by the Department of Defense to help develop and manufacture new vaccines to fight encephalitic viruses that cause inflammation of the brain. [More]
UC Berkeley researchers make major improvement in CRISPR-Cas9 gene editing technology

UC Berkeley researchers make major improvement in CRISPR-Cas9 gene editing technology

University of California, Berkeley, researchers have made a major improvement in CRISPR-Cas9 technology that achieves an unprecedented success rate of 60 percent when replacing a short stretch of DNA with another. [More]

MedNet Solutions attains record-setting corporate growth in 2015

MedNet Solutions, an innovative SaaS-based eClinical technology company that supports the entire spectrum of clinical research, is pleased to announce the attainment of record-setting corporate growth in 2015. [More]
NextSource Biotechnology announces FDA approval of Gleostine (lomustine) 5 mg capsules

NextSource Biotechnology announces FDA approval of Gleostine (lomustine) 5 mg capsules

NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States. [More]
Artificial pancreas moves closer to becoming a reality

Artificial pancreas moves closer to becoming a reality

As the accuracy, reliability, adoption, and successful use of Continuous Glucose Monitoring (CGM) continue to increase, the ultimate goal of combining CGM with an insulin pump and sophisticated algorithms for automating the control and suspension of insulin infusion--known as the "artificial pancreas"--moves closer to becoming a reality. [More]
Insulet donates $10,000 each to ADA and JDRF to improve lives of people living with diabetes

Insulet donates $10,000 each to ADA and JDRF to improve lives of people living with diabetes

Insulet Corporation, the leader in tubeless insulin pump technology with its OmniPod Insulin Management System, today announced that is has donated $10,000 each to the American Diabetes Association and the Juvenile Diabetes Research Foundation. [More]
First patients treated in Phase 1b trial of pembrolizumab with REOLYSIN in advanced pancreatic adenocarcinoma

First patients treated in Phase 1b trial of pembrolizumab with REOLYSIN in advanced pancreatic adenocarcinoma

Oncolytics Biotech Inc. today announced that the first patients have been treated in a Phase 1b study of pembrolizumab (KEYTRUDA) in combination with REOLYSIN (pelareorep) and chemotherapy in patients with advanced pancreatic adenocarcinoma (REO 024). [More]
BENEPALI granted marketing authorization in the EU for treatment of chronic inflammatory diseases

BENEPALI granted marketing authorization in the EU for treatment of chronic inflammatory diseases

The joint venture between Biogen and Samsung BioLogics, Samsung Bioepis, has been granted European Commission (EC) approval for BENEPALI , an etanercept biosimilar referencing Enbrel. [More]

Professor Graham Boulnois appointed as chairman of Medicines Technologies Catapult

Life sciences businessman and academic Professor Graham Boulnois has been appointed as chairman of the Medicines Technologies Catapult, one of the latest technology and innovation centres set to open this year. [More]
UM SOM selected to work with BARDA to develop radiologic and nuclear countermeasures

UM SOM selected to work with BARDA to develop radiologic and nuclear countermeasures

University of Maryland School of Medicine Department of Radiation Oncology Chair and Professor William F. Regine, MD, FACR, FACRO, and UM SOM Dean E. Albert Reece, MD, PhD, MBA, announced today that researchers at the UM SOM have been selected as key contractors by the Biomedical Advanced Research and Development Authority, for its Radiation Nuclear Animal Model Development program. [More]
Researchers engineer antibodies that could potently neutralize two deadliest strains of Ebola virus

Researchers engineer antibodies that could potently neutralize two deadliest strains of Ebola virus

Researchers at Albert Einstein College of Medicine and the U.S. Army Medical Research Institute of Infectious Diseases have engineered the first antibodies that can potently neutralize the two deadliest strains of the virus that causes Ebola hemorrhagic fever. [More]
Advertisement
Advertisement